Modulation of the inflammatory process by statins.

Area of Science:

• Pharmacology
• Immunology
• Cardiovascular Medicine

Background:

• Statins are primary agents for lowering cholesterol by inhibiting HMG-CoA reductase, crucial for cholesterol synthesis.
• Their lipid-lowering effects improve treatment and prevention of ischemic heart disease, reducing inflammatory markers like C-reactive protein.
• Emerging evidence suggests statins possess significant non-lipid-lowering properties impacting immune and inflammatory pathways.

Purpose of the Study:

• To explore the immunomodulatory effects of statins beyond their lipid-lowering capabilities.
• To investigate the role of statins in inflammation and immune system modulation.
• To highlight statin-induced changes in immune cell function and inflammatory mediator synthesis.

Main Methods:

• Review of clinical trials and research data on statin effects.
• Analysis of statin's impact on inflammatory markers and immune cell expression.
• In vitro studies examining statin effects on cytokine synthesis in vascular cells.

Main Results:

• Statins inhibit major histocompatibility class II expression and T-cell activation.
• They reduce monocyte receptor expression, adhesion molecule activity, and leukocyte adhesion.
• Statins decrease IL-6 synthesis in vascular smooth muscle cells and influence other inflammatory mediators.

Conclusions:

• Statins exhibit significant immunomodulatory and anti-inflammatory effects.
• These non-lipid-lowering actions contribute to their therapeutic benefits in cardiovascular and cerebrovascular diseases.
• Further research into statin's immune-modulating properties is warranted.